DBV Technologies (NASDAQ:DBVT) Shares Down 7.1% – Should You Sell?

Shares of DBV Technologies S.A. (NASDAQ:DBVT) traded down 7.1% on Thursday . The stock traded as low as $11.39 and last traded at $11.3110. Approximately 224,641 shares traded hands during trading, a decline of 25% from the average daily volume of 300,439 shares. The stock had previously closed at $12.17.

Analysts Set New Price Targets

DBVT has been the topic of several recent analyst reports. Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Citizens Jmp boosted their target price on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Finally, Weiss Ratings downgraded shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Price Performance

The firm’s 50-day moving average is $13.64 and its 200-day moving average is $17.00. The company has a market capitalization of $725.07 million, a P/E ratio of -3.29 and a beta of -0.95.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Allworth Financial LP purchased a new stake in shares of DBV Technologies in the fourth quarter valued at approximately $32,000. Royal Bank of Canada raised its holdings in shares of DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after acquiring an additional 2,928 shares in the last quarter. Personal CFO Solutions LLC bought a new stake in shares of DBV Technologies in the first quarter valued at about $264,000. Cetera Investment Advisers lifted its stake in DBV Technologies by 93.4% in the first quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock worth $530,000 after acquiring an additional 12,243 shares during the period. Finally, AdvisorShares Investments LLC bought a new position in DBV Technologies during the 1st quarter worth about $1,052,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.